Karol E. Watson

Work Stress Linked to Mortality — But Only in Men with Cardiometabolic Disease

The role of stress as a risk factor in cardiometabolic disease still needs clarification. These investigators linked individual-level data on prevalent

Cholesterol Lowering Can Reduce Mortality: Results of a Meta-Analysis

The earliest lipid-lowering trials enrolled individuals with very high cholesterol levels and found robust reductions in cardiovascular events. Some

Validity of the Seattle Angina Questionnaire in Women: Confirmed

The Seattle Angina Questionnaire (SAQ) was originally developed in a predominately male population and was never specifically validated in women.

A Weight Loss Drug Without Overall Increased Cardiovascular Events

Lorcaserin is a selective serotonin 2C receptor agonist that modulates appetite and that has been demonstrated to facilitate modest long-term weight

PAD Plus a Major Adverse Limb Event Means Very High Risk

In the manufacturer-sponsored COMPASS trial, low-dose rivaroxaban (2.5 mg twice daily) plus aspirin was shown to have significant cardiovascular

For Stable Chest Pain, CCTA Evaluation Lowers Longer-Term Risk

In the SCOT-HEART randomized trial (NCT01149590), coronary computed tomographic angiography (CCTA) was shown to improve diagnostic certainty in

Exercise Training Can Reverse Vascular Stiffness

Heart failure, whether with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), is associated with a sedentary lifestyle. Because

Black Patients with Heart Failure Are Less Likely to See a Cardiologist in the ICU

Black patients have a higher lifetime risk for heart failure (HF) and the highest HF mortality. Studies have shown that in-hospital survival is higher

A Novel Mechanism Causing Hypertriglyceridemia

There are many known mechanisms leading to hypertriglyceridemia. Now, researchers have described a novel one — GPIHBP1 autoantibodies that cause severe

Antidrug-Antibody Formation: A Problem in PCSK9 Therapy?

Therapy based on monoclonal antibodies (mAbs) might induce unwanted immunogenicity, which may lead to minor problems, such as injection-site reactions or flu-like symptoms, or to more serious problems, such as anaphylaxis or loss of drug efficacy. Two recent manufacturer-supported reports describe antidrug-antibody formation in patients exposed to mAb-based proprotein convertase subtilisin–kexin type 9 (PCSK9) therapies.nnRidker and colleagues reported data from six studies on approximately 4000 patients randomized to the experimental PCSK9 inhibitor bococizumab (a “humanized” …